Kalaris Therapeutics, Inc. Share Price & Technical Analysis
KLRS · $5.20 (+5.69%)
Healthcare / Biotechnology
$5.20
+5.69%
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-11% return in May, -17% avg return in past 3 year May month.
-40% return in 2026, -47% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 6% | 19% | -43% | -11% | -11% | – | – | – | – | – | – | – | -40% |
| 25 | -11% | 4% | -20% | -21% | -54% | -7% | 0% | 52% | 49% | -14% | 22% | 40% | 39% |
| 24 | 6% | 2% | 1% | 5% | -5% | -6% | 2% | 1% | 6% | 15% | -40% | -23% | -36% |
| 23 | 10% | 16% | -42% | -12% | 8% | -10% | -3% | -5% | -33% | -30% | 23% | -65% | -143% |
| 22 | -37% | 8% | -25% | -34% | -15% | -1% | 18% | 66% | 8% | -12% | 7% | -33% | -50% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Uptrend
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$106.68M
P/E ratio
—
52W high
$11.88
52W low
$2.14
Volume
87,341
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Kalaris Therapeutics, Inc. share price today?
- Kalaris Therapeutics, Inc. (KLRS) last traded around $5.20 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does KLRS have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for KLRS. Download the app for real-time alerts.
- How can I analyze Kalaris Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.